Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NCT02490085Phase 2Completed
Phase 2, randomised, open-label trial in type 2 diabetes mellitus (T2DM), sponsored by Montreal Clinical Research Institute. Primary endpoint: Percentage of time of plasma glucose concentrations spent in the target range at 24 hours. Started Oct 2015; status: completed.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on NCT02490085.